Related Experiment Video
Updated: Aug 5, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Divergent Trajectories of Pediatric All-Form Tuberculosis and Multidrug-Resistant Tuberculosis from 1990 to 2021
Qing Zhang1,2,3, De Chang1,2,3
1Department of Pulmonary and Critical Care Medicine at the Seventh Medical Center, Chinese PLA General Hospital, Beijing 100700, China.
Abstract:
Using Global Burden of Disease 2021 modeled estimates, we assessed the burden, temporal trends, and inequalities of pediatric all-form tuberculosis (TB) and multidrug-resistant TB (MDR-TB) from 1990 to 2021 across 204 countries and territories. Compared with all-form TB, pediatric MDR-TB showed a distinct and less favorable estimated trajectory. Although GBD-based estimates suggested overall declines in pediatric all-form TB incidence and mortality, the MDR-to-all-form ratio increased worldwide for both incidence and mortality, suggesting a growing proportional contribution of MDR-TB within the estimated pediatric TB burden. In 2021, pediatric MDR-TB remained concentrated in low- and low-middle-SDI settings, where modeled socioeconomic inequalities appeared to become more pronounced over time. Mortality relative to incidence was highest among children aged under 5 years, with particularly elevated and imprecise mortality-to-incidence ratios for MDR-TB. Sex disparities also evolved differently by disease type: they generally narrowed for all-form TB but were more heterogeneous and in some settings widened for MDR-TB. These GBD-based findings suggest that progress in overall pediatric TB control may not have translated evenly to drug-resistant disease and highlight the need for pediatric TB strategies that explicitly address drug resistance, early childhood vulnerability, and inequitable access to diagnosis and treatment. Due to the sparsity of global pediatric data, no independent external validation was performed; findings are based on internal sensitivity analyses of GBD estimates.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
